BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 15047916)

  • 1. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
    Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
    Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selective estrogen receptor modulators in breast cancer prevention.
    Li F; Dou J; Wei L; Li S; Liu J
    Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of breast cancer in the older patient.
    Minton SE
    Hematol Oncol Clin North Am; 2000 Feb; 14(1):113-30. PubMed ID: 10680075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
    Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
    Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
    Dickler MN; Norton L
    Ann N Y Acad Sci; 2001 Dec; 949():134-42. PubMed ID: 11795345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
    Vogel VG
    Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).
    Lo SS; Vogel VG
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):97-111. PubMed ID: 14687600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raloxifene in breast cancer prevention.
    Gennari L; Merlotti D; Paola VD; Nuti R
    Expert Opin Drug Saf; 2008 May; 7(3):259-70. PubMed ID: 18462184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
    Zujewski J
    Environ Mol Mutagen; 2002; 39(2-3):264-70. PubMed ID: 11921197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention of breast cancer: implications for postmenopausal women.
    Fabian CJ; Kimler BF
    Drugs Aging; 2002; 19(1):43-78. PubMed ID: 11929326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture.
    Jordan VC
    Ann N Y Acad Sci; 2001 Dec; 952():60-72. PubMed ID: 11795444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
    Park WC; Jordan VC
    Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen to raloxifene and beyond.
    O'Regan RM; Jordan VC
    Semin Oncol; 2001 Jun; 28(3):260-73. PubMed ID: 11402436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing breast cancer in high-risk women, 2008.
    Vogel VG
    Oncology (Williston Park); 2008 May; 22(6):666-73; discussion 679, 682, 684. PubMed ID: 18561555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
    Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.